<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159613">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01707394</url>
  </required_header>
  <id_info>
    <org_study_id>CV185-118</org_study_id>
    <secondary_id>2012-001581-15</secondary_id>
    <nct_id>NCT01707394</nct_id>
  </id_info>
  <brief_title>Study to Evaluate a Single Dose of Apixaban in Pediatric Subjects at Risk for a Thrombotic Disorder</brief_title>
  <official_title>Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Apixaban in Pediatric Subjects at Risk for a Venous or Arterial Thrombotic Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CV185118 is a single dose Apixaban PK/PD study in pediatric subjects. The objective of this
      study is primarily to study the PK/PD of Apixaban in pediatric subjects at risk for
      thrombosis
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Estimated area under the plasma concentration-time curve [AUC(INF)] of Apixaban</measure>
    <time_frame>Up to 26 hours, post dose (from Day 1 to Day 2)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum estimated plasma concentration (Cmax) of Apixaban</measure>
    <time_frame>Up to 26 hours, post dose (from Day 1 to Day 2)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimated time at which maximum plasma concentration occurs (Tmax) of Apixaban</measure>
    <time_frame>Up to 26 hours, post dose (from Day 1 to Day 2)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety is measured by adverse event reports and the results of vital sign measurements, electrocardiograms, physical examinations, and clinical laboratory tests</measure>
    <time_frame>Up to 30 Days after last dosing</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Time Frame: From Day 1 to Day 2 (Up to 26 hours, post dose), and 30 Day after last dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics will be measured by anti-Factor Xa confirmed by analysis of anti-Factor Xa</measure>
    <time_frame>Up to 26 hours, post dose (from Day 1 to Day 2)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Group 1: Apixaban (low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban solution 0.21 mg/m2 by mouth or by nasogastric tube (NG) or gastronomy tube (G-tube) using a dosing syringe on the morning of Day 1
Group 1: Neonates up to 27 days of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2:  Apixaban (low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban solution 1.08 mg/ m2 by mouth or by nasogastric tube (NG) or gastronomy tube (G-tube) using a dosing syringe on the morning of Day 1
Group 2:  â‰¥ 28 days to &lt; 2 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Apixaban (low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban solution 1.17  mg/ m2 by mouth or by nasogastric tube (NG) or gastronomy tube (G-tube) using a dosing syringe on the morning of Day 1
Group 3:   2 years to &lt; 6 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: Apixaban (low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban solution 1.80  mg/ m2 by mouth or by nasogastric tube (NG) or gastronomy tube (G-tube) using a dosing syringe on the morning of Day 1
Group 4:   6 years to &lt;12 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: Apixaban (low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban solution 2.19 mg/ m2 by mouth or by nasogastric tube (NG) or gastronomy tube (G-tube) using a dosing syringe on the morning of Day 1
Group 5:   12 years to &lt;18 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <arm_group_label>Group 1: Apixaban (low dose)</arm_group_label>
    <arm_group_label>Group 2:  Apixaban (low dose)</arm_group_label>
    <arm_group_label>Group 3: Apixaban (low dose)</arm_group_label>
    <arm_group_label>Group 4: Apixaban (low dose)</arm_group_label>
    <arm_group_label>Group 5: Apixaban (low dose)</arm_group_label>
    <other_name>BMS-562247</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with stable disease that are at risk for a venous or arterial thrombotic
             Neonates &gt; 37 weeks gestation at birth to &lt; 18 years of age

        Exclusion Criteria:

          -  Current or recent (within 3 months of study drug administration) gastrointestinal
             disease or gastrointestinal surgery that, in the opinion of the investigator and the
             BMS Medical Monitor, could impact the absorption of the study drug

          -  Active bleeding or high risk of bleeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>37 Weeks</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arkansas Children'S Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parthak Prodhan, Site 0004</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children'S Hospital Of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Nugent, Site 0025</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Connecticut Children'S Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Boruchov, Site 0026</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medstar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amal Abu-Ghosh, Site 0017</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaser Diab, Site 0022</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children'S Healthcare Of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikhil Chanani, Site 0019</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kosair Charities Pediatric Clinical Research Unit</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice Sullivan, Site 0001</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children'S Mercy Hospital And Clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keith August, Site 0013</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0006</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0024</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke Children'S Hospital</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Ofori-Amanfo, Site 0015</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0003</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Children'S Hospital</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew S Freiberg, Site 0002</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital Of Pittsburgh Of Upmc</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sriya Gunawardena, Site 0016</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital Of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheila Hanson, Site 0005</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Alberta - Edmonton Clinic Health Academy</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1C9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark J Belletrutti, Site 0014</last_name>
      <phone>780-492-3163</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Hospital For Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonardo Brandao, Site 0012</last_name>
      <phone>416-813-7654</phone>
      <phone_ext>28378</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0021</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0027</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>04530</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0008</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mexico City</city>
        <state>Distrito Federal</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0007</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44260</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0010</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0009</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
    <country>Israel</country>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>October 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
